01763.HK
China Isotope & Radiation Corporation
HKSE · Healthcare · Medical - Devices · CN
HKD 11.74
−4.40%Oct 22, 2026, 02:06 UTC
China Isotope & Radiation Corp. said its 93.1533%-owned subsidiary China Isotope & Radiation Corp. plans to seek investors through a public listing process, offering newly issued shares representing a 20% stake and targeting proceeds for research, production-base construction, capacity expansion and working capital.
Source:Oct 12, 2026, 03:25 UTC
China Isotope & Radiation Corp. said its subsidiary China Isotope & Radiation Corp. received a drug registration certificate from the National Medical Products Administration for a 50 mg urea-13C powder breath-test kit.
Source:Sep 23, 2026, 01:54 UTC
China Isotope & Radiation Corporation announced that its subsidiary CNNC High Tech's Lu-177 API Drug Master File (DMF) passed review and was accepted by the U.S. FDA, allowing downstream drugmakers to reference it.
Source:Sep 8, 2026, 01:37 UTC
China Isotope & Radiation completed the issuance of 500 million yuan of technology innovation corporate bonds with a coupon rate of 1.5%.
Source:Sep 1, 2026, 06:17 UTC
China Isotope & Radiation and others established a new company, Zhonghe Fuyuan (Beijing) Technology Co., Ltd., which will engage in machinery R&D and sales, manufacturing of mechanical and electrical equipment, sales of Class II and III radiation devices, and production of radioactive isotopes.
Source:Aug 31, 2026, 01:40 UTC
China Isotope & Radiation announced that Zhang Junqi resigned as General Manager and executive director due to work adjustment, effective last Friday (August 28), and the board appointed Li Penghui as General Manager.
Source:Aug 12, 2026, 07:08 UTC
China Isotope & Radiation and CNNC (Zhejiang) Innovation Co., Ltd. jointly established a new company, CNNC Fuzhi (Beijing) Technology Co., Ltd., which will engage in AI and IoT businesses.
Source: